Qiagen in deals with Alacris, EyeSense

Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) announced separate deals on Tuesday with Alacris Theranostics GmbH (Berlin, Germany) and EyeSense AG (Basel, Switzerland). Qiagen acquired a minority stake in Alacris and gained an exclusive option to access all biomarkers discovered by Alacris, which is using its modeling system to develop individualized cancer treatment strategies based on genomic profiles. Alacris will be eligible for royalties. ...